EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Engaging the PD-1 pathway in systemic sclerosis attenuates inflammation-driven fibrosis

Maithri Aspari, Voon Ong, Klaus Søndergaard, Esben Næser, Malene Hvid, Kim Ravnskjaer, Angela Y Y Tam, Shiwen Xu, Xinyue Bian, Henry Lopez, Christopher P Denton, David Abraham und 2 weitere

Annals of the Rheumatic Diseases · 2026

DOI: 10.1016/j.ard.2026.01.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2026. Verfasst von Maithri Aspari und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine, Aarhus University, Aarhus, Denmark. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, Pulmonary Fibrosis, Scleroderma, Diffuse. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Arthritis Society, Lundbeck Foundation, Foundation for Research in Rheumatology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: The study elucidates the impact of the programmed cell death protein 1 (PD-1) pathway on immune activation and fibrosis in diffuse cutaneous systemic sclerosis (dcSSc). METHODS: We obtained blood and skin biopsies from patients with dcSSc and healthy controls (HCs). Soluble PD-1 was measured in serum. Human recombinant PD-1 protein (PD-1:Fc) and anti-PD-1 antibodies were used to stimulate peripheral blood mononuclear cells (PBMCs), HC, and systemic sclerosis (SSc) dermal fibroblast cultures, and cocultures. PD-1-positive (PD-1pos) and PD-1-negative (PD-1neg) populations of dcSSc PBMCs were characterised. We used a murine bleomycin model of pulmonary injury to study the effect of PD-1:Fc on pulmonary fibrosis in vivo. RESULTS: Soluble and cellular PD-1 were elevated in dcSSc compared to HC. Naïve fibroblasts differed between HC and dcSSc, but did not respond to PD-1:Fc treatment. Transforming growth factor β (TGF-β)-stimulated fibroblasts from dcSSc displayed a myofibroblast profile with a differential clustering compared to HC fibroblasts. PD-1:Fc downregulated the secretion of extracellular matrix (ECM) proteins, surface markers of fibroblast activation, and the production of inflammatory cytokines in TGF-β-stimulated in vitro cultures. PD-1pos SSc T cells had a different and more regulatory transcriptional profile than the PD-1neg T cell population. In vivo studies demonstrated that treatment with PD-1:Fc inhibited the development of lung fibrosis and the production of profibrotic cytokines. CONCLUSIONS: Administrating PD-1:Fc attenuated inflammation and ECM protein production in dcSSc in vitro models and decreased systemic inflammation and pulmonary fibrosis in the bleomycin-induced fibrosis model in mice. Our data indicate that modulating the PD-1/PD-Ligand 1 axis represents a novel therapeutic avenue in dcSSc.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Programmed Cell Death 1 ReceptorPulmonary FibrosisScleroderma, DiffuseHumansAnimalsMiceFibroblastsMaleBleomycinSkinFemaleFibrosisDisease Models, AnimalInflammationCells, CulturedTransforming Growth Factor betaSignal TransductionLeukocytes, MononuclearScleroderma, SystemicMiddle Aged

Substanzen

Programmed Cell Death 1 ReceptorPDCD1 protein, humanBleomycinTransforming Growth Factor beta

Autor:innen und Institutionen

  • Department of Biomedicine, Aarhus University, Aarhus, Denmark.
  • Department of Inflammation and Rare Diseases, UCL Royal Free Campus, London, UK.
  • Department of Rheumatology, Aarhus University, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Department of Biomedicine, Aarhus University, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark.
  • Department of Inflammation and Rare Diseases, UCL Royal Free Campus, London, UK; MuriGenics, Vallejo, San Francisco, CA, USA.

Förderung

  • Arthritis Society
  • Lundbeck Foundation
  • Foundation for Research in Rheumatology

Zitieren

APA

Aspari, M., Ong, V., Søndergaard, K., Næser, E., Hvid, M., Ravnskjaer, K., Tam, A. Y. Y., Xu, S., Bian, X., Lopez, H., Denton, C. P., Abraham, D., Deleuran, B., & Greisen, S. R. (2026). Engaging the PD-1 pathway in systemic sclerosis attenuates inflammation-driven fibrosis. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2026.01.008

Vancouver

Aspari M, Ong V, Søndergaard K, Næser E, Hvid M, Ravnskjaer K, et al. Engaging the PD-1 pathway in systemic sclerosis attenuates inflammation-driven fibrosis. Annals of the Rheumatic Diseases. 2026. doi:10.1016/j.ard.2026.01.008

BibTeX
@article{Aspari2026,
  author = {Aspari, Maithri and Ong, Voon and Søndergaard, Klaus and Næser, Esben and Hvid, Malene and Ravnskjaer, Kim and Tam, Angela Y Y and Xu, Shiwen and Bian, Xinyue and Lopez, Henry and Denton, Christopher P and Abraham, David and Deleuran, Bent and Greisen, Stinne R},
  title = {Engaging the PD-1 pathway in systemic sclerosis attenuates inflammation-driven fibrosis},
  journal = {Annals of the Rheumatic Diseases},
  year = {2026},
  doi = {10.1016/j.ard.2026.01.008}
}
Kostenlos starten →